Developing break-through treatments
for dry eye disease

AxeroVision was founded in 2016 to develop novel therapies for the treatment of ophthalmic inflammatory diseases, such as Dry Eye Disease (DED) and Meibomian Gland Dysfunction (MGD).  AXR-159 is being developed for the treatment of chronic DED.  AXR-270 is being developed for the short-term treatment of DED.  Both assets have achieved clinical proof-of-concept.

 
 
 

Company Strategy

AxeroVision_ded.jpg

AxeroVision was founded to develop novel therapies for the treatment of Dry Eye Disease (DED) and other ophthalmic inflammatory diseases that address the underlying inflammatory processes, thus providing a more meaningful clinical benefit for patients.

Pipeline

AxeroVision_DED2.jpg

AxeroVision programs are in late-stage clinical development.

Financing & Partnering

AxeroVision_DED3.jpg

We are seeking equity investment and/or a strategic partner to fund continued development of our programs.